[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase 1 Study to Assess Safety and Tolerability of Odronextamab (REGN1979) an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, and Cemiplimab (REGN2810), an Anti-Programmed Death-1 Monoclonal Antibody in Patients With B-Cell Malignancies (CLIO-1)


Description

This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose regimen for the combination with odronextamab. This study is also looking at several other research questions, including: * What side effects may happen from taking the study drugs * How effective the study drugs are against the disease * How much study drug is in the blood at different times * Whether the body makes substances or protein called antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)

Trial Eligibility

Key Inclusion Criteria: 1. Have documented CD20+ aggressive B-cell NHL that is either not responsive to or relapsed after at least 2 prior lines of systemic therapy, for whom treatment with an anti-CD20 antibody may be appropriate. In addition, prior treatments should at least contain an anti-CD20 antibody and an alkylating agent. 2. Must have at least 1 nodal lesion (≥1.5 cm), or at least one extranodal lesion with longest transverse diameter (LDi) greater than 1.0 cm, documented by diagnostic imaging (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]). 3. Eastern Cooperative Oncology Group (ECOG) performance status ≤1 4. Adequate bone marrow and hepatic function, as defined in the protocol 5. Willing and able to comply with clinic visits and study-related procedures 6. Provide signed informed consent Key Exclusion Criteria: 1. Primary central nervous system (CNS) lymphoma, or known or suspected CNS involvement by non-primary CNS NHL 2. History of or current relevant CNS pathology, as described in the protocol 3. Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-mediated adverse events (iAEs) 4. Prior therapies, as described in the protocol 5. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection or other uncontrolled infection 6. Cytomegalovirus infection as noted by detectable levels on peripheral blood polymerase chain reaction (PCR) assay until the infection is well controlled. 7. Known hypersensitivity to both allopurinol and rasburicase 8. Pregnant or breastfeeding women 9. Women of childbearing potential, or men who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose, as defined in the protocol 10. Patients prior diagnosis of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) Note: Other protocol-defined Inclusion/Exclusion criteria apply

Study Info

Organization

Regeneron Pharmaceuticals


Primary Outcome

Incidence of dose limiting toxicities (DLTs) of cemiplimab in combination with odronextamab


Outcome Timeframe Up to 28 days

NCTID NCT02651662

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2016-01-11

Completion Date 2026-12-25

Enrollment Target 62

Interventions

DRUG cemiplimab

DRUG odronextamab

Locations Recruiting

University of California Los Angeles Medical Center

United States, California, Santa Monica


Johns Hopkins University

United States, Maryland, Baltimore


Dana Farber/Harvard Cancer Center - PO box 849168

United States, Massachusetts, Boston


Harvard Medical School - Beth Israel Deaconess Medical Center

United States, Massachusetts, Boston


Cancer & Hematology Centers of Western Michigan

United States, Michigan, Grand Rapids


Interested in joining this trial?

Our dedicated patient navigators are here to support you by reviewing the eligibility criteria to see if you might qualify for this trial.

newsletter icon

Get the latest thought leadership on your Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.